Bausch + Lomb Overview
- Year Founded
-
1852
- Status
-
Public
- Employees
-
13,500
- Stock Symbol
-
BLCO
- Investments
-
36
- Share Price
-
$12.04
- (As of Tuesday Closing)
Bausch + Lomb General Information
Description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact Information
Website
www.bausch.comCorporate Office
- 400 Somerset Corporate Boulevard
- Bridgewater, NJ 08807
- United States
Corporate Office
- 400 Somerset Corporate Boulevard
- Bridgewater, NJ 08807
- United States
Bausch + Lomb Timeline
Bausch + Lomb Stock Performance
As of 22-Apr-2025, Bausch + Lomb’s stock price is $12.04. Its current market cap is $4.25B with 353M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.04 | $12.03 | $10.47 - $21.28 | $4.25B | 353M | 3.12K | -$0.90 |
Bausch + Lomb Financials Summary
As of 31-Dec-2024, Bausch + Lomb has a trailing 12-month revenue of $4.79B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 10,742,012 | 10,742,012 | 10,186,746 | 7,649,493 |
| Revenue | 4,791,000 | 4,791,000 | 4,146,000 | 3,768,000 |
| EBITDA | 586,000 | 586,000 | 484,000 | 592,000 |
| Net Income | (317,000) | (317,000) | (260,000) | 6,000 |
| Total Assets | 13,469,000 | 13,469,000 | 13,442,000 | 11,144,000 |
| Total Debt | 4,784,000 | 4,784,000 | 4,562,000 | 2,436,000 |
Bausch + Lomb Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bausch + Lomb Comparisons
Industry
Financing
Details
Bausch + Lomb Competitors (8)
One of Bausch + Lomb’s 8 competitors is Alcon, a Corporate Backed or Acquired company based in Geneva, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alcon | Corporate Backed or Acquired | Geneva, Switzerland | ||||
| The Cooper Companies | Corporation | San Ramon, CA | ||||
| RxSight | Formerly VC-backed | Aliso Viejo, CA | ||||
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Medtronic | Corporation | Minneapolis, MN |
Bausch + Lomb Patents
Bausch + Lomb Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-D922595-S1 | Light therapy device | Active | 09-Jan-2020 | ||
| US-D921212-S1 | Light therapy device | Active | 09-Jan-2020 | ||
| US-20200375681-A1 | Detachable finger-activated surgical control device | Inactive | 03-Jun-2019 | ||
| CA-3132335-A1 | Glycophospholipid polymeric network and use thereof | Pending | 29-Apr-2019 | ||
| US-20200339710-A1 | Glycophospholipid polymeric network and use thereof | Active | 29-Apr-2019 | C08B37/0063 |
Bausch + Lomb Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bausch + Lomb Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bausch + Lomb Investments & Acquisitions (36)
Bausch + Lomb’s most recent deal was a Later Stage VC with Character Biosciences for . The deal was made on 20-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Character Biosciences | 20-Mar-2025 | Later Stage VC | Drug Discovery | ||
| Whitecap Biosciences | 13-Jan-2025 | Merger/Acquisition | Drug Discovery | ||
| Trukera Medical | 19-Jul-2024 | Merger/Acquisition | Diagnostic Equipment | ||
| ELIOS Vision | 01-Jan-2024 | Merger/Acquisition | Surgical Devices | ||
| Novartis (Eyecare Portfolio) | 29-Sep-2023 | Corporate Asset Purchase | Buildings and Property |
Bausch + Lomb ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
19.57 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Healthcare
Industry
of 587
Rank
Percentile
Medical Supplies
Subindustry
of 58
Rank
Percentile
Bausch + Lomb Exits (5)
Bausch + Lomb’s most recent exit was on 01-Jan-2015 from Checkedup. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Checkedup | 01-Jan-2015 | Completed |
|
||
| Cutting Edge Manufacturing | 01-Jan-2000 | Completed |
|
||
| Miracle-Ear | 01-Jan-1993 | Completed |
|
||
| Charles River Laboratories International | 01-Jan-1984 | Completed |
|
||
| Minnesota Eye Consultants | Corporate | Completed |
Bausch + Lomb Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| ELIOS Vision | Los Angeles, CA | 2019 | |
| Xiidra | Dublin, Ireland | 2016 | |
| Paragon Bioteck | Portland, OR | 2008 | |
| AcuFocus | Irvine, CA | 2001 | |
| Trukera Medical | Southlake, TX | 1996 |
Bausch + Lomb FAQs
-
When was Bausch + Lomb founded?
Bausch + Lomb was founded in 1852.
-
Where is Bausch + Lomb headquartered?
Bausch + Lomb is headquartered in Bridgewater, NJ.
-
What is the size of Bausch + Lomb?
Bausch + Lomb has 13,500 total employees.
-
What industry is Bausch + Lomb in?
Bausch + Lomb’s primary industry is Therapeutic Devices.
-
Is Bausch + Lomb a private or public company?
Bausch + Lomb is a Public company.
-
What is Bausch + Lomb’s stock symbol?
The ticker symbol for Bausch + Lomb is BLCO.
-
What is the current stock price of Bausch + Lomb?
As of 22-Apr-2025 the stock price of Bausch + Lomb is $12.04.
-
What is the current market cap of Bausch + Lomb?
The current market capitalization of Bausch + Lomb is $4.25B.
-
What is Bausch + Lomb’s current revenue?
The trailing twelve month revenue for Bausch + Lomb is $4.79B.
-
Who are Bausch + Lomb’s competitors?
Alcon, The Cooper Companies, RxSight, Novo Nordisk, and Medtronic are some of the 8 competitors of Bausch + Lomb.
-
What is Bausch + Lomb’s annual earnings per share (EPS)?
Bausch + Lomb’s EPS for 12 months was -$0.90.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
